JPMorgan raised the firm’s price target on AbbVie (ABBV) to $260 from $250 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: